Oxford BioMedica Plc (OXB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH7057D
- Pages: 73
- November 2018
- Total Views:1281
- Region : Europe
- GlobalData
- Equity Research Report
Details
Summary
Oxford BioMedica plc (Oxford Biomedica) is a gene and cell therapy company that focuses on developing novel treatments for serious diseases. The company along with its subsidiaries has developed LentiVector, a sector leading lentiviral vector delivery platform. It has also built a platform of special cutting-edge technologies and capabilities, based on LentiVector. Based on LentiVector delivery platform Oxford BioMedica has developed a portfolio of gene and cell therapy product candidates in cancer, ophthalmology and central nervous system (CNS) therapy areas. The company also provides lentiviral vector bioprocessing and process development services to partners. Oxford BioMedica is headquartered Oxford, the UK.
Oxford BioMedica Plc (OXB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxford BioMedica Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Oxford BioMedica Plc, Medical Devices Deals, 2012 to YTD 2018 10
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Oxford BioMedica Acquires Windrush Court Office and Laboratory Facilities for USD5 Million 13
Partnerships 14
Boehringer Ingelheim, Imperial College London, University of Oxford, University of Edinburgh, Imperial Innovations, and Oxford BioMedica Enter into Collaboration Agreement 14
Oxford BioMedica Enters into Agreement with Cell Therapy Catapult, Stratophase and Synthace 16
Oxford BioMedica Enters into Agreement with Novartis 17
Oxford BioMedica Enters into Agreement with Green Cross 18
Oxford BioMedica Enters into Agreement with Novartis 19
Licensing Agreements 20
Axovant Sciences Enters into Licensing Agreement with Oxford BioMedica 20
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 22
Orchard Therapeutics Expands Licensing Agreement with Oxford BioMedica 23
Oxford BioMedica Exercises Option for Licensing Agreement with GlaxoSmithKline 24
Oxford BioMedica Enters into Licensing Agreement with Novartis for LentiVector 25
Oxford BioMedica Amends Licensing Agreement With Sanofi 26
Oxford BioMedica Enters into Licensing Agreement with MolMed 27
Immune Design Licensing Agreement with Oxford BioMedica 28
Equity Offering 29
Oxford BioMedica to Raise USD28.4 Million in Private Placement of Shares 29
Oxford BioMedica Raises USD15.3 Million in Private Placement of Shares 30
Oxford BioMedica to Raise USD11.5 Million in Private Placement of Shares 32
Oxford BioMedica Raises USD33 Million in Private Placement of Shares 34
Oxford BioMedica Raises USD2.6 Million in Public Offering 36
Oxford BioMedica Completes Private Placement Of Shares For USD 17 Million 37
Oxford BioMedica Completes Rights Offering Of Shares For USD 1 Million 38
Oxford BioMedica Plc-Key Competitors 39
Oxford BioMedica Plc-Key Employees 40
Oxford BioMedica Plc-Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Strategy And Business Planning 42
Sep 13, 2018: Oxford Biomedica announces further capacity expansion with new facility 42
Financial Announcements 43
Sep 13, 2018: Oxford Biomedica interim results for the six months ended 30 June 2018 43
Mar 15, 2018: Oxford Biomedica: Preliminary Results for the Year Ended 31 December 2017 49
Aug 17, 2017: Oxford Biomedica: Interim Results For The Six Months Ended 30 June 2017 59
Mar 16, 2017: Oxford Biomedica Announces Preliminary Results for the Year Ended 31 December 2016 64
Corporate Communications 65
Jul 02, 2018: Oxford BioMedica Announces Directorate Change 65
Jun 04, 2018: Oxford BioMedica Announces Directorate Change 66
Mar 15, 2018: Board Change: Oxford BioMedica Appoints Heather Preston as Non-Executive Director 67
Aug 29, 2017: Oxford BioMedica: Stuart Paynter starts as new Chief Financial Officer 68
Feb 28, 2017: Oxford BioMedica Appoints New Chief Financial Officer 69
Government and Public Interest 70
Jan 23, 2018: Oxford BioMedica announces GBP3 million grant awarded by Innovate UK 70
Other Significant Developments 71
Mar 28, 2018: Gyros Protein Technologies installs two Gyrolab xPlore systems at Oxford BioMedica for gene and cell therapy applications 71
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73
List Of Figure
List of Figures
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Oxford BioMedica Plc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxford BioMedica Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxford BioMedica Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Oxford BioMedica Plc, Medical Devices Deals, 2012 to YTD 2018 10
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Oxford BioMedica Acquires Windrush Court Office and Laboratory Facilities for USD5 Million 13
Boehringer Ingelheim, Imperial College London, University of Oxford, University of Edinburgh, Imperial Innovations, and Oxford BioMedica Enter into Collaboration Agreement 14
Oxford BioMedica Enters into Agreement with Cell Therapy Catapult, Stratophase and Synthace 16
Oxford BioMedica Enters into Agreement with Novartis 17
Oxford BioMedica Enters into Agreement with Green Cross 18
Oxford BioMedica Enters into Agreement with Novartis 19
Axovant Sciences Enters into Licensing Agreement with Oxford BioMedica 20
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 22
Orchard Therapeutics Expands Licensing Agreement with Oxford BioMedica 23
Oxford BioMedica Exercises Option for Licensing Agreement with GlaxoSmithKline 24
Oxford BioMedica Enters into Licensing Agreement with Novartis for LentiVector 25
Oxford BioMedica Amends Licensing Agreement With Sanofi 26
Oxford BioMedica Enters into Licensing Agreement with MolMed 27
Immune Design Licensing Agreement with Oxford BioMedica 28
Oxford BioMedica to Raise USD28.4 Million in Private Placement of Shares 29
Oxford BioMedica Raises USD15.3 Million in Private Placement of Shares 30
Oxford BioMedica to Raise USD11.5 Million in Private Placement of Shares 32
Oxford BioMedica Raises USD33 Million in Private Placement of Shares 34
Oxford BioMedica Raises USD2.6 Million in Public Offering 36
Oxford BioMedica Completes Private Placement Of Shares For USD 17 Million 37
Oxford BioMedica Completes Rights Offering Of Shares For USD 1 Million 38
Oxford BioMedica Plc, Key Competitors 39
Oxford BioMedica Plc, Key Employees 40
Oxford BioMedica Plc, Other Locations 41
Oxford BioMedica Plc, Subsidiaries 41
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Oxford BioMedica Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Oxford BioMedica plc (Oxford Biomedica) is a gene and cell therapy company that focuses on developing novel treatments for serious diseases. The company along with its subsidiaries has developed LentiVector, a sector leading lentiviral vector delivery platform. It has also built a platform of special cutting-edge technologies and capabilities, based on LentiVector. Based on LentiVector delivery platform Oxford BioMedica has developed a portfolio of gene and cell therapy product candidates in cancer, ophthalmology and central nervous system (CNS) therapy areas. The company also provides lentiviral vector bioprocessing and process development services to partners. Oxford BioMedica is headquartered Oxford, the UK.
Oxford BioMedica Plc (OXB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxford BioMedica Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Oxford BioMedica Plc, Medical Devices Deals, 2012 to YTD 2018 10
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Oxford BioMedica Acquires Windrush Court Office and Laboratory Facilities for USD5 Million 13
Partnerships 14
Boehringer Ingelheim, Imperial College London, University of Oxford, University of Edinburgh, Imperial Innovations, and Oxford BioMedica Enter into Collaboration Agreement 14
Oxford BioMedica Enters into Agreement with Cell Therapy Catapult, Stratophase and Synthace 16
Oxford BioMedica Enters into Agreement with Novartis 17
Oxford BioMedica Enters into Agreement with Green Cross 18
Oxford BioMedica Enters into Agreement with Novartis 19
Licensing Agreements 20
Axovant Sciences Enters into Licensing Agreement with Oxford BioMedica 20
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 22
Orchard Therapeutics Expands Licensing Agreement with Oxford BioMedica 23
Oxford BioMedica Exercises Option for Licensing Agreement with GlaxoSmithKline 24
Oxford BioMedica Enters into Licensing Agreement with Novartis for LentiVector 25
Oxford BioMedica Amends Licensing Agreement With Sanofi 26
Oxford BioMedica Enters into Licensing Agreement with MolMed 27
Immune Design Licensing Agreement with Oxford BioMedica 28
Equity Offering 29
Oxford BioMedica to Raise USD28.4 Million in Private Placement of Shares 29
Oxford BioMedica Raises USD15.3 Million in Private Placement of Shares 30
Oxford BioMedica to Raise USD11.5 Million in Private Placement of Shares 32
Oxford BioMedica Raises USD33 Million in Private Placement of Shares 34
Oxford BioMedica Raises USD2.6 Million in Public Offering 36
Oxford BioMedica Completes Private Placement Of Shares For USD 17 Million 37
Oxford BioMedica Completes Rights Offering Of Shares For USD 1 Million 38
Oxford BioMedica Plc-Key Competitors 39
Oxford BioMedica Plc-Key Employees 40
Oxford BioMedica Plc-Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Strategy And Business Planning 42
Sep 13, 2018: Oxford Biomedica announces further capacity expansion with new facility 42
Financial Announcements 43
Sep 13, 2018: Oxford Biomedica interim results for the six months ended 30 June 2018 43
Mar 15, 2018: Oxford Biomedica: Preliminary Results for the Year Ended 31 December 2017 49
Aug 17, 2017: Oxford Biomedica: Interim Results For The Six Months Ended 30 June 2017 59
Mar 16, 2017: Oxford Biomedica Announces Preliminary Results for the Year Ended 31 December 2016 64
Corporate Communications 65
Jul 02, 2018: Oxford BioMedica Announces Directorate Change 65
Jun 04, 2018: Oxford BioMedica Announces Directorate Change 66
Mar 15, 2018: Board Change: Oxford BioMedica Appoints Heather Preston as Non-Executive Director 67
Aug 29, 2017: Oxford BioMedica: Stuart Paynter starts as new Chief Financial Officer 68
Feb 28, 2017: Oxford BioMedica Appoints New Chief Financial Officer 69
Government and Public Interest 70
Jan 23, 2018: Oxford BioMedica announces GBP3 million grant awarded by Innovate UK 70
Other Significant Developments 71
Mar 28, 2018: Gyros Protein Technologies installs two Gyrolab xPlore systems at Oxford BioMedica for gene and cell therapy applications 71
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73
List Of Figure
List of Figures
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Oxford BioMedica Plc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxford BioMedica Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxford BioMedica Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Oxford BioMedica Plc, Medical Devices Deals, 2012 to YTD 2018 10
Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Oxford BioMedica Acquires Windrush Court Office and Laboratory Facilities for USD5 Million 13
Boehringer Ingelheim, Imperial College London, University of Oxford, University of Edinburgh, Imperial Innovations, and Oxford BioMedica Enter into Collaboration Agreement 14
Oxford BioMedica Enters into Agreement with Cell Therapy Catapult, Stratophase and Synthace 16
Oxford BioMedica Enters into Agreement with Novartis 17
Oxford BioMedica Enters into Agreement with Green Cross 18
Oxford BioMedica Enters into Agreement with Novartis 19
Axovant Sciences Enters into Licensing Agreement with Oxford BioMedica 20
Bioverativ Enters into Licensing Agreement with Oxford BioMedica 22
Orchard Therapeutics Expands Licensing Agreement with Oxford BioMedica 23
Oxford BioMedica Exercises Option for Licensing Agreement with GlaxoSmithKline 24
Oxford BioMedica Enters into Licensing Agreement with Novartis for LentiVector 25
Oxford BioMedica Amends Licensing Agreement With Sanofi 26
Oxford BioMedica Enters into Licensing Agreement with MolMed 27
Immune Design Licensing Agreement with Oxford BioMedica 28
Oxford BioMedica to Raise USD28.4 Million in Private Placement of Shares 29
Oxford BioMedica Raises USD15.3 Million in Private Placement of Shares 30
Oxford BioMedica to Raise USD11.5 Million in Private Placement of Shares 32
Oxford BioMedica Raises USD33 Million in Private Placement of Shares 34
Oxford BioMedica Raises USD2.6 Million in Public Offering 36
Oxford BioMedica Completes Private Placement Of Shares For USD 17 Million 37
Oxford BioMedica Completes Rights Offering Of Shares For USD 1 Million 38
Oxford BioMedica Plc, Key Competitors 39
Oxford BioMedica Plc, Key Employees 40
Oxford BioMedica Plc, Other Locations 41
Oxford BioMedica Plc, Subsidiaries 41
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Oxford BioMedica Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
: +91 9015378249
Related Reports
Page 69 | 
May 2022
Page 76 | April 2022
Page 68 | March 2022
Page 78 | March 2022
Page 56 | October 2021